PSMA ADC

Drug Profile

PSMA ADC

Alternative Names: Monomethylauristatin E-antiPSMA monoclonal antibody conjugate; PSMA Antibody Drug Conjugate

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Progenics Pharmaceuticals; PSMA Development Company
  • Developer Brown University; Progenics Pharmaceuticals; Rhode Island Hospital; University of Texas at Dallas
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Prostate cancer

Most Recent Events

  • 09 Mar 2017 Progenics Pharmaceuticals has patent protection for PSMA ADC in USA and Europe
  • 09 Mar 2017 Progenics Pharmaceuticals has patents pending for PSMA ADC in USA
  • 21 Jun 2016 Progenics Pharmaceuticals in-licenses CHO-M Cell Line and SUREtechnology platform from Selexis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top